Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in ...

PDS Biotechnology (PDSB) announced the publication of circulating tumor DNA results for its lead immunotherapy candidate, Versamune HPV, in ...

Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune ...

PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination ...

Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune® HPV ...

VELDHOVEN, the Netherlands - ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. This regular update of the transactions conducted under ...

PDS Biotech leadership will also hold one-on-one meetings during the conference. To register for the in-person event, please contact your B. Riley Securities representative. One week following the ...

PDS Biotech leadership will also hold one-on-one meetings during the conference. To register for the in-person event, please contact your B. Riley Securities representative. One week following the ...